{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-265627","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2024-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.187676+00:00","generated_at":"2026-05-29T18:25:39.500231+00:00","sec_items":["1.01","5.02","8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Sarepta enters $500M upfront license deal with Arrowhead for siRNA therapies; GC resigns","bullets":["$500M upfront cash to Arrowhead; up to $300M near-term payments; up to $180M per program development milestones, $700M per program sales milestones; tiered royalties up to low double digits.","Sarepta purchases 11.9M shares of Arrowhead for $325M in a private placement, with 180-day lock-up and standstill for up to 5 years.","Programs include clinical siRNA candidates for FSHD, DM1, ataxias, IPF, and pre-clinical for Huntington's; Sarepta can select six additional discovery targets.","Arrowhead leads initial development and manufacturing; Sarepta assumes responsibility at transition points and holds global commercialization rights.","EVP Chief General Counsel Ryan Brown resigns effective Nov 26; Cristin Rothfuss named successor as EVP General Counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-265627","json":"https://secwatch.observer/filing/0001193125-24-265627.json","markdown":"https://secwatch.observer/filing/0001193125-24-265627.md","text":"https://secwatch.observer/filing/0001193125-24-265627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/d856104d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T18:25:39.500231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97947a5676","claim":"Ryan Brown resigned as Executive Vice President, Chief General Counsel at Sarepta Therapeutics, Inc..","evidence_excerpt":"Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Chief General Counsel"}]},{"claim_id":"b0d04d7414","claim":"Cristin Rothfuss was appointed as Executive Vice President, General Counsel at Sarepta Therapeutics, Inc..","evidence_excerpt":"Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, General Counsel"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}